Kodiak Sciences Inc. (KOD)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 03:19PM EDT. Market open.
| Previous close | 3.7700 |
| Open | 3.8200 |
| Bid | 4.0000 x 200 |
| Ask | 4.0500 x 100 |
| Day's range | 3.7536 - 4.0500 |
| 52-week range | 1.3700 - 9.8000 |
| Volume | |
| Avg. volume | 804,881 |
| Market cap | 210.665M |
| Beta (5Y monthly) | 2.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.9700 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.25 |
PR NewswireKodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that nine scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, being held from May 5 – 9 in Seattle, Washington.
Simply Wall St.Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
ZacksKodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
© 2024 Yahoo. All rights reserved.